Wells Fargo & Company Aclaris Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,590 shares of ACRS stock, worth $9,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,590
Previous 4,590
-0.0%
Holding current value
$9,960
Previous $5,000
120.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ACRS
# of Institutions
87Shares Held
60.6MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$30.9 Million21.95% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$19.3 Million4.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$9.39 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$7.32 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$6.52 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $145M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...